Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 203

    1.

    Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.

    Hoffmann JN, Vollmar B, Laschke MW, Fertmann JM, Jauch KW, Menger MD.

    Crit Care. 2005;9 Suppl 4:S33-7. Epub 2005 Aug 25. Review.PMID: 16168073 [PubMed - indexed for MEDLINE]Related articles

    2.

    Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.

    Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Fertmann J, Schildberg FW, Menger MD.

    Crit Care Med. 2004 Apr;32(4):1011-7.PMID: 15071394 [PubMed - indexed for MEDLINE]Related articles

    3.

    Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein C.

    Hoffmann JN, Fertmann JM, Jauch KW.

    Curr Opin Crit Care. 2006 Oct;12(5):426-30. Review.PMID: 16943720 [PubMed - indexed for MEDLINE]Related articles

    4.

    The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure.

    Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD.

    Shock. 2000 Nov;14(5):528-34.PMID: 11092685 [PubMed - indexed for MEDLINE]Related articles

    5.

    Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway.

    Joyce DE, Nelson DR, Grinnell BW.

    Crit Care Med. 2004 May;32(5 Suppl):S280-6. Review.PMID: 15118531 [PubMed - indexed for MEDLINE]Related articles

    6.

    Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia.

    Hoffman JN, Fertmann JM, Vollmar B, Laschke MW, Jauch KW, Menger MD.

    Shock. 2008 Jan;29(1):133-9.PMID: 18246604 [PubMed - indexed for MEDLINE]Related articles

    7.

    New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).

    Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JM.

    Crit Care. 2005;9 Suppl 4:S38-45. Epub 2005 Aug 25. Review.PMID: 16168074 [PubMed - indexed for MEDLINE]Related articles

    8.

    Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.

    Esmon CT.

    Crit Care Med. 2001 Jul;29(7 Suppl):S48-51; discussion 51-2. Review.PMID: 11445734 [PubMed - indexed for MEDLINE]Related articles

    9.

    Activated protein C versus protein C in severe sepsis.

    Yan SB, Dhainaut JF.

    Crit Care Med. 2001 Jul;29(7 Suppl):S69-74. Review.PMID: 11445737 [PubMed - indexed for MEDLINE]Related articles

    10.

    Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia.

    Gierer P, Hoffmann JN, Mahr F, Menger MD, Mittlmeier T, Gradl G, Vollmar B.

    Crit Care Med. 2007 Aug;35(8):1966-71.PMID: 17568327 [PubMed - indexed for MEDLINE]Related articles

    11.

    Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats.

    Schoots IG, Levi M, van Vliet AK, Maas AM, Roossink EH, van Gulik TM.

    Crit Care Med. 2004 Jun;32(6):1375-83.PMID: 15187522 [PubMed - indexed for MEDLINE]Related articles

    12.

    Coagulation inhibitor replacement during sepsis: useless?

    Hoffman JN, Faist E.

    Crit Care Med. 2000 Sep;28(9 Suppl):S74-6. Review.PMID: 11007203 [PubMed - indexed for MEDLINE]Related articles

    13.

    Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications.

    Okajima K.

    Curr Vasc Pharmacol. 2004 Apr;2(2):125-33. Review.PMID: 15320513 [PubMed - indexed for MEDLINE]Related articles

    14.

    Human recombinant erythropoietin protects the striated muscle microcirculation of the dorsal skinfold from postischemic injury in mice.

    Contaldo C, Meier C, Elsherbiny A, Harder Y, Trentz O, Menger MD, Wanner GA.

    Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H274-83. Epub 2007 Mar 2.PMID: 17337594 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    A chronic model for intravital microscopic study of microcirculatory disorders and leukocyte/endothelial cell interaction during normotensive endotoxemia.

    Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD.

    Shock. 1999 Nov;12(5):355-64.PMID: 10565610 [PubMed - indexed for MEDLINE]Related articles

    16.

    Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model.

    Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y.

    Crit Care Med. 2005 Feb;33(2):368-72.PMID: 15699841 [PubMed - indexed for MEDLINE]Related articles

    17.

    Dehydroepiandrosterone protects the microcirculation of muscle flaps from ischemia-reperfusion injury by reducing the expression of adhesion molecules.

    Ayhan S, Tugay C, Norton S, Araneo B, Siemionow M.

    Plast Reconstr Surg. 2003 Jun;111(7):2286-94.PMID: 12794471 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia.

    Lehmann C, Scheibe R, Schade M, Meissner K, Gründling M, Usichenko T, Wendt M, Hung O, Whynot S, Murphy M, Pavlovic D.

    Can J Anaesth. 2008 Mar;55(3):155-62.PMID: 18310625 [PubMed - indexed for MEDLINE]Related articles

    19.

    Thrombin and leukocyte recruitment in endotoxemia.

    Woodman RC, Teoh D, Payne D, Kubes P.

    Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1338-45.PMID: 10993801 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Activated protein C in the cardioplegic solution on a porcine model of coronary ischemia-reperfusion has deleterious hemodynamic effects.

    Fernández JA, Vento AE, Jormalainen M, Griffin JH, Pesonen E, Syrjälä M, Repo H, Jansson SE, Rämö OJ, Petäjä J.

    Cardiovasc Drugs Ther. 2006 Apr;20(2):113-21.PMID: 16761191 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data